• CDMO
    CDMO
  • platforms
    Platforms
  • Pipeline
  • licensing
    Licensing

Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines

From discovery to phase II clinical trial.

Even the most promising vaccines can fail in the transition from laboratory to large-scale production. At Intravacc, we understand the challenges of vaccine development and offer strategies to help you successfully reduce risks and costs. How? By giving you access to our knowledgeable and experienced team, our proprietary vaccine production platforms, and our vaccine pipeline.

Discover our CDMO services

Learn about our platforms

Review our vaccine pipeline

Intravacc at a glance

at the glance 01

100+

Highly Qualified employees.

at the glance 02

50+

Customers worldwide.

at the glance 03

300+

Scientific publications.

at the glance 04

2000+

State-of-the-art facilities.

Latest news

See all

Icon: category Press releases

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Press releases 2024/03/28

See full article

Icon: category Press releases

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

Press releases 2024/03/26

See full article

Icon: category Webinar

Webinar: Gaurav Kanojia, PhD

Webinar 2024/02/27

See full article

Icon: category Corporate

Meet Paul, Intravacc's new Director QA/QC & EHS

Corporate 2024/01/29

See full article

Icon: category Press releases

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Press releases 2024/01/11

See full article

Icon: category Event

World Vaccine Congress – Washington USA, 1-4 Apr. ‘24

Event 2024/01/01

See full article

Icon: category Corporate

Intravacc sales process update

Corporate 2023/12/28

See full article

Icon: category Press releases

Introducing our new website!

Press releases 2023/12/21

See full article

The magic is in the knowledge

Make your vaccine idea reality with less risk and at lower cost. See how our know-how and expertise can streamline your development program.

Find out more

Success stories

Highlights of our milestones, the accomplishments of our team, and the successes of our partners.

Intravacc – Trusted vaccine manufacturing company

Intravacc has been declared to be one of the "5 Most Trusted Vaccine ...

Virgil Schijns, CSO – Visiting Professor in Glasgow

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the ...

Avacc® 11 – favorable Preclinical Data

Intravacc Announces Favorable Preclinical Data for its Candidate ...

Intravacc launches phase I clinical trial of Avacc® 10

Intravacc launches phase I clinical trial of Avacc® 10, an intranasal ...

A unique pipeline of vaccine candidates open for licensing.

pipeline tabelle
AvaccPlatformLicensingDownload
Avacc® 2 Cell-Vacc Open for licensing
Avacc® 3 OMV-Vacc Out licensed in certain regions, please contact us
Avacc® 5 Cell-Vacc Open for licensing
Avacc® 10 OMV-Vacc Open for licensing
Avacc® 11 OMV-Vacc Open for licensing
Avacc® 12 OMV-Vacc Open for licensing
Avacc® 13 OMV-Vacc Out licensed in certain regions, please contact us
Avacc® 31 Con-Vacc Open for licensing

Our partners

bcht
CDbio
celonic
Cepi
cimcure
dzne
LGchem
minha
NIH

Contact us

You can send us an email:
info@intravacc.nl

Reach out to Business Development: 
BD@intravacc.nl

Or pick up the phone: 
+31 30 792 03 00

You can also just fill out the contact form on the right.

We look forward to hearing from you!

 

Contact form

Subscribe to our newsletter